The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis

The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations : Systematic Review and Meta-Analysis / Amirhossein Sahebkar, Maria-Corina Serban, Peter Penson, Camelia Gurban, Sorin Ursoniu, Peter P. Toth, Steven R. Jones, Giuseppe Lippi , Kazuhiko Kotani , Karam Kostner, Manfredi Rizzo, Jacek Rysz, Maciej Banach

  • Drugs 77 (2017) 11 (July), p. 1187–1197
  • PMID: 28573436
  • PMCID: PMC5501893
  • DOI: 10.1007/s40265-017-0767-4


Introduction: Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with lower circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less well studied.

Aims: We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) [Lp(a)] through a meta-analysis of available randomized controlled trials (RCTs) and observational studies.

Methods: This study was registered in the PROSPERO database (CRD42016036890). Scopus, MEDLINE and EMBASE were searched from inception until 22 March 2016 to identify studies investigating the effect of tamoxifen on Lp(a) values in humans. Meta-analysis was performed using an inverse variance-weighted, random-effects model with standardized mean difference (SMD) as the effect size estimate.

Results: Meta-analysis of five studies with 215 participants suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment (SMD -0.41, 95% confidence interval -0.68 to -0.14, p = 0.003). This effect was robust in the sensitivity analysis.

Conclusions: Meta-analysis suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment. Further well-designed trials are required to validate these results.

Original document


1 July 2017
Banach, Maciej
Gurban, Camelia
Jones, Steven R.
Kostner, Karam
Kotani, Kazuhiko
Lippi, Giuseppe
Penson, Peter
Rizzo, Manfredi
Rysz, Jacek
Sahebkar, Amirhossein
Serban, Maria-Corina
Toth, Peter P.
Ursoniu, Sorin
Iran, Islamic Republic of
United Kingdom
United States of America
Other organisations
Instytut „Centrum Zdrowia Matki Polki” (ICZMP) - Polish Mother’s Memorial Hospital Research Institute
Jichi Medical University
Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
Liverpool John Moores University (LJMU)
Mashhad University of Medical Sciences (MUMS)
Università degli Studi di Palermo - University of Palermo
Università degli Studi di Verona - University of Verona
Universitatea de Medicină și Farmacie "Victor Babeș" (UMF Timișoara) - Victor Babeș University of Medicine and Pharmacy, Timișoara
University of Alabama at Birmingham (UAB)
University of Queensland (UQ)
University of Western Australia (UWA)
Uniwersytet Medyczny w Łodzi - Medical University of Łódź
Uniwersytet Zielonogórski - University of Zielona Góra
Doping classes
S4. Hormone And Metabolic Modulators
Selective estrogen receptor modulators (SERMS)
Medical terms
Health effects
Legitimate Medical Treatment
Document category
Scientific article
Document type
Pdf file
Date generated
10 January 2022
Date of last modification
18 January 2022
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period